Results 191 to 200 of about 1,000,292 (319)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

MOS is a key regulator of meiotic midbody assembly and prevents abnormal divisions in mouse eggs and their polar bodies. [PDF]

J Cell Sci
Cairo G, Haseeb MA, Boyce Joy Z, Schindler K, Lacefield S.   +4 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Source Field Plate Incorporated Monolithic Inverters Composed of GaN-Based CMOS-HEMTs with Double-2DEG Channels and Fin-Gated Multiple Nanochannels. [PDF]

Materials (Basel)
Chen HY, Lee HY, Lee H, Wu YR, Lee CT.
europepmc   +1 more source

MOS Current Mode Logic with Capacitive Coupling [PDF]

, 2012
Kirti Gupta, Neeta Pandey, Maneesha Gupta   +2 more
openalex   +1 more source

Single-step chemical vapour deposition of anti-pyramid MoS₂/WS₂ vertical heterostructures

, 2021
Xueyin Bai, Shisheng Li, Susobhan Das, Luojun Du, Yunyun Dai, Lide Yao, R. Ramesh, Mingde Du, Harri Lipsanen, Zhipei Sun   +9 more
openalex   +2 more sources

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Morvan syndrome in a patient with progressing metastatic thymoma and myasthenia gravis. [PDF]

BMJ Case Rep
Öztosun G, Salemme R, Kaminski HJ, Conway ST.   +3 more
europepmc   +1 more source

$ZZ\to {\ell }^{+}{\ell }^{-}{\ell }^{\prime +}{\ell }^{\prime -}$ cross-section measurements and search for anomalous triple gauge couplings in 13 TeV $pp$ collisions with the ATLAS detector

Physical Review, 2018
Measurements of ZZ production in the ℓ+ℓ−ℓ′+ℓ′− channel in proton–proton collisions at 13 TeV center-of-mass energy at the Large Hadron Collider are presented. The data correspond to 36.1 fb−1 of collisions collected by the ATLAS experiment in 2015 and 2016. Here ℓ and ℓ′ stand for electrons or muons.
Aaboud, M., Aad, G., Abbott, B., Abdinov, O., Abeloos, B., Abidi, S. H., AbouZeid, O. S., Abraham, N. L., Abramowicz, H., Abreu, H., Abreu, R., Abulaiti, Y., Acharya, B. S., Adachi, S., Adamczyk, L., Adelman, J., Adersberger, M., Adye, T., Affolder, A. A., Afik, Y., Agatonovic-Jovin, T., Agheorghiesei, C., Aguilar-Saavedra, J. A., Ahlen, S. P., Ahmadov, F., Aielli, G., Akatsuka, S., Akerstedt, H., Åkesson, T. P. A., Akilli, E., Akimov, A. V., Alberghi, G. L., Albert, J., Albicocco, P., Alconada Verzini, M. J., Alderweireldt, S. C., Aleksa, M., Aleksandrov, I. N., Alexa, C., Alexander, G., Alexopoulos, T., Alhroob, M., Ali, B., Aliev, M., Alimonti, G., Alison, J., Alkire, S. P., Allbrooke, B. M. M., Allen, B. W., Allport, P. P., Aloisio, A., Alonso, A., Alonso, F., Alpigiani, C., Alshehri, A. A., Alstaty, M. I., Alvarez Gonzalez, B., Álvarez Piqueras, D., Alviggi, M. G., Amadio, B. T., Amaral Coutinho, Y., Amelung, C., Amidei, D., Amor Dos Santos, S. P., Amoroso, S., Amundsen, G., Anastopoulos, C., Ancu, L. S., Andari, N., Andeen, T., Anders, C. F., Anders, J. K., Anderson, K. J., Andreazza, A., Andrei, V., Angelidakis, S., Angelozzi, I., Angerami, A., Anisenkov, A. V., Anjos, N., Annovi, A., Antel, C., Antonelli, M., Antonov, A., Antrim, D. J., Anulli, F., Aoki, M., Aperio Bella, L., Arabidze, G., Arai, Y., Araque, J. P., Araujo Ferraz, V., Arce, A. T. H., Ardell, R. E., Arduh, F. A., Arguin, J-F., Argyropoulos, S., Arik, M., Armbruster, A. J., Armitage, L. J., Arnaez, O., Arnold, H., Arratia, M., Arslan, O., Artamonov, A., Artoni, G., Artz, S., Asai, S., Asbah, N., Ashkenazi, A., Asquith, L., Assamagan, K., Astalos, R., Atkinson, M., Atlay, N. B., Augsten, K., Avolio, G., Axen, B., Ayoub, M. K., Azuelos, G., Baas, A. E., Baca, M. J., Bachacou, H., Bachas, K., Backes, M., Bagnaia, P., Bahmani, M., Bahrasemani, H., Baines, J. T., Bajic, M., Baker, O. K., Baldin, E. M., Balek, P., Balli, F., Balunas, W. K., Banas, E., Bandyopadhyay, A., Banerjee, Sw., Bannoura, A. A. E., Barak, L., Barberio, E. L., Barberis, D., Barbero, M., Barillari, T., Barisits, M-S, Barkeloo, J. T., Barklow, T., Barlow, N., Barnes, S. L., Barnett, B. M., Barnett, R. M., Barnovska-Blenessy, Z., Baroncelli, A., Barone, G., Barr, A. J., Barranco Navarro, L., Barreiro, F., Barreiro Guimarães da Costa, J., Bartoldus, R., Barton, A. E., Bartos, P., Basalaev, A., Bassalat, A., Bates, R. L., Batista, S. J., Batley, J. R., Battaglia, M., Bauce, M., Bauer, F., Bawa, H. S., Beacham, J. B., Beattie, M. D., Beau, T., Beauchemin, P. H., Bechtle, P., Beck, H. P., Beck, H. C., Becker, K., Becker, M., Becot, C., Beddall, A. J., Beddall, A., Bednyakov, V. A., Bedognetti, M., Bee, C. P., Beermann, T. A., Begalli, M., Begel, M., Behr, J. K., Bell, A. S., Bella, G., Bellagamba, L., Bellerive, A., Bellomo, M., Belotskiy, K., Beltramello, O., Belyaev, N. L., Benary, O., Benchekroun, D., Bender, M.   +199 more
openaire  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source